{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=5", "query": { "condition": "Refractory Malignancy", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 5764, "total_pages": 577, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T05:09:50.108Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00005942", "title": "Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myelomonocytic Leukemia", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation" ], "interventions": [ { "name": "liposomal daunorubicin citrate", "type": "DRUG" }, { "name": "semaxanib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-11-09T05:09:50.108Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005942" }, { "nct_id": "NCT00003183", "title": "Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Hope Cancer Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 64, "start_date": "1997-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-11-09T05:09:50.108Z", "location_count": 2, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003183" }, { "nct_id": "NCT04864522", "title": "Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "SLAMF7 FPBMC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-08", "completion_date": "2023-11", "has_results": false, "last_update_posted_date": "2023-11-21", "last_synced_at": "2026-11-09T05:09:50.108Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04864522" }, { "nct_id": "NCT01285102", "title": "Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Metastases", "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Stage IV Colon Cancer", "Stage IV Rectal Cancer" ], "interventions": [ { "name": "irinotecan-eluting beads", "type": "COMBINATION_PRODUCT" }, { "name": "hepatic artery embolization", "type": "PROCEDURE" } ], "intervention_types": [ "COMBINATION_PRODUCT", "PROCEDURE" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2010-10", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2021-12-20", "last_synced_at": "2026-11-09T05:09:50.108Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01285102" }, { "nct_id": "NCT00743288", "title": "Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2008-07", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-05-08", "last_synced_at": "2026-11-09T05:09:50.108Z", "location_count": 4, "location_summary": "Bakersfield, California • West Hollywood, California • Denver, Colorado + 1 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00743288" }, { "nct_id": "NCT03399773", "title": "Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Lymphoblastic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid Cell Neoplasm", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome With Excess Blasts" ], "interventions": [ { "name": "Dilanubicel", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Electrocardiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "10 Years to 65 Years" }, "enrollment_count": 31, "start_date": "2022-05-10", "completion_date": "2027-04-02", "has_results": true, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-11-09T05:09:50.108Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03399773" }, { "nct_id": "NCT00389701", "title": "Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sparrow Regional Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2006-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-11-09T05:09:50.108Z", "location_count": 1, "location_summary": "Lansing, Michigan", "locations": [ { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00389701" }, { "nct_id": "NCT00514267", "title": "An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Tumors" ], "interventions": [ { "name": "YM 155", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2007-05", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2015-08-13", "last_synced_at": "2026-11-09T05:09:50.108Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00514267" }, { "nct_id": "NCT00994500", "title": "Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Burkitt Lymphoma", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Medulloepithelioma", "Childhood Meningioma", "Childhood Mixed Glioma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Childhood Oligodendroglioma", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 20, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-11-09T05:09:50.108Z", "location_count": 6, "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00994500" }, { "nct_id": "NCT01769222", "title": "Ipilimumab and Local Radiation for Selected Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Colon Cancer", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Melanoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Rectal Cancer", "Recurrent Small Lymphocytic Lymphoma", "Refractory Hairy Cell Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2013-02", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-11-09T05:09:50.108Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01769222" } ] }